ACN
29
-11
NAVI
32
8
PRU
45
-9
EMR
51
-3
CMI
42
4
GE
70
3
COST
50
2
HSIC
51
6
AMG
50
-2
ORLY
47
3
MRK
43
-2
FITB
59
3
R
66
-2
L
41
4
LOW
30
-9
KR
59
2
NWS
70
2
NI
75
2
PHM
46
4
EQT
65
11
ACN
29
-11
NAVI
32
8
PRU
45
-9
EMR
51
-3
CMI
42
4
GE
70
3
COST
50
2
HSIC
51
6
AMG
50
-2
ORLY
47
3
MRK
43
-2
FITB
59
3
R
66
-2
L
41
4
LOW
30
-9
KR
59
2
NWS
70
2
NI
75
2
PHM
46
4
EQT
65
11
Financhill
Back

Lyra Therapeutics 10K Form

Sell
39

LYRA
Lyra Therapeutics

Last Price:
$10.67
Seasonality Move:
12.18%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive LYRA News And Ratings

See the #1 stock for the next 7 days that we like better than LYRA

LYRA Financial Statistics

Sales & Book Value

Annual Sales: $1.5M
Cash Flow: $-8.8M
Price / Cash Flow: 0
Annual Sales: $2.94
Price / Book: 3.66

Profitability

EPS (TTM): -60.50000
Net Income (TTM): $-79.5M
Gross Margin: --
Return on Equity: -275.07%
Return on Assets: -90.89%

Lyra Therapeutics Earnings Forecast

Key Lyra Therapeutics Financial Ratios

  • The Research & Development expenses have been 2,853.06% of Revenue.
  • The Net Earning history of LYRA is -6,090.94% of Total Revenues.
  • Per Share Earnings over the last 7 years have been positive in 3 years.

Lyra Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: LYRA
CUSIP: 55234L
Website: lyratherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 2.96
Quick Ratio: 2.77

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

LYRA Technical Analysis vs Fundamental Analysis

Sell
39
Lyra Therapeutics (LYRA) is a Sell

Is Lyra Therapeutics a Buy or a Sell?

  • Lyra Therapeutics stock is rated a Sell
    The current Lyra Therapeutics [LYRA] share price is $10.45. The Score for LYRA is 39, which is 22% below its historic median score of 50, and infers higher risk than normal.